PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.

On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

Innovation for sustainable plastic packaging - 04/09/2024

Liquid Plug & Play: eco-designed plastic packaging – not just for ultrasound gel

In the healthcare industry tons of consumables such as ultrasound gel go to waste because packaging can’t be completely emptied. An invention called Liquid Plug & Play could offer a solution for the future. This innovation, which consists of a reusable outer shell and a disposable product pouch for viscous substances, can be completely emptied. It also prevents cross-contamination and offers many other benefits.

Dossier - 14/06/2016

CRISPR/Cas – genome editing is becoming increasingly popular

The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary diseases.

Dossier - 24/05/2012

Biochips microsystems technology for the life sciences

Nanoscale robots and intelligent measurement systems in arteries, fingernail-sized DNA chips that can be used to analyze thousands of genes in tiny samples, intelligent DNA microsensors – the trend in the life sciences is moving towards miniaturization.

Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.

BioFluidix GmbH, a spin-off resulting from the cooperation between Hahn-Schickard and the Department of Microsystems Engineering at the University of Freiburg, is now part of the Swiss Hamilton Bonaduz AG.

NeuroQ project - 26/07/2023

Quantum sensors for exoskeletons: can quantum physics beat paralysis?

Could people suddenly be able to move again decades after being paralysed? State-of-the-art quantum sensors integrated in exoskeletons could make this possible. Technology being developed as part of the BMBF-funded NeuroQ beacon project by researchers from organisations including the Fraunhofer IAF, the Charité in Berlin and the University of Stuttgart might achieve even more: besides facilitating movement, it could also help cure paralysis.

Article - 26/07/2019

New test assay leads to discovery of new influenza virus infection route

Researchers from the University of Freiburg have recently discovered a completely new mechanism that influenza viruses use to infect cells. This discovery was partly made possible by a so-called emulsion coupling assay - an extremely sensitive, digital detection method developed by Actome GmbH in collaboration with scientists from the Freiburg University of Applied Sciences and Hahn-Schickard. The assay is used to count individual molecules and…

Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…

3D bioprinting is a great hope in the field of regenerative medicine to produce miniaturized tissues and organ precursors with biological functionality. Today, however, scientists are still working on the challenge of producing a printable and at the same time compatible starting material.

Lab-on-a-chip - 11/11/2020

Microfluidic platform for the best possible cancer therapy

Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

Researchers of Karlsruhe Institute of Technology (KIT) and Voxalytic GmbH developed a new method that allows, for the first time, to elucidate the chiral structure of molecules – the exact spatial arrangement of the atoms – by nuclear magnetic resonance (NMR) spectroscopy. This important step in the development of new drugs used to be a time-consuming process until now.

The challenge: if conventional speaking valves are used improperly, dangerous overpressure can occur, which can cause serious complications and even death. In a collaboration at the University of Freiburg, researchers developed a speaking valve with an integrated pressure release valve and an acoustic warning signal, inspired by the trapping mechanism of the carnivorous bladderwort plant Utricularia vulgaris.

In the “Cluster4Future” QSens of the Universities of Stuttgart and Ulm, scientists, companies and start-ups are researching quantum sensors with a wide range of potential applications. The Federal Ministry of Education and Research is funding QSens for a further three years as part of “Clusters4Future”.

From human intestines to the bottom of the sea: Microorganisms populate nearly any habitat, no matter how hostile it is. Their great variety of survival strategies is of huge potential in biotechnology. Most of these organisms, however, are unknown, because they cannot be cultivated.

Expert interview - 08/03/2023

How do new active substances from university research reach patients?

Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer

On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.

The Deep-Tech Start-Up memetis GmbH from Germany, which produces the world’s most compact and lightest commercially available valves driven by shape memory alloys, announces a new partnership with Fluid-o-Tech S.r.l., an Italian innovation and market leader in the field of fluid-pumps.

Article - 29/01/2019

Targeted RNA editing with the body’s own enzyme activity

Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…

Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.

Prof. Dr. Harald Gießen from the Institute of Physics (4) as well as Prof. Dr. Alois Herkommer and Dr. Simon Thiele from the Institute of Applied Optics at the University of Stuttgart received the Gips Schüle Research Award 2021 on October 19, 2021. The researchers were awarded the prize, which is valued at EUR 50,000.